A detailed history of Twinbeech Capital LP transactions in Ultragenyx Pharmaceutical Inc. stock. As of the latest transaction made, Twinbeech Capital LP holds 17,813 shares of RARE stock, worth $969,561. This represents 0.01% of its overall portfolio holdings.

Number of Shares
17,813
Holding current value
$969,561
% of portfolio
0.01%

Shares

6 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

BUY
$37.42 - $51.61 $666,562 - $919,328
17,813 New
17,813 $732,000
Q3 2022

Nov 14, 2022

BUY
$39.96 - $66.14 $4.4 Million - $7.28 Million
110,066 New
110,066 $4.56 Million
Q3 2021

Nov 15, 2021

SELL
$77.92 - $102.4 $1.4 Million - $1.84 Million
-17,927 Closed
0 $0
Q2 2021

Aug 16, 2021

BUY
$92.19 - $115.71 $1.65 Million - $2.07 Million
17,927 New
17,927 $1.71 Million
Q1 2021

May 17, 2021

SELL
$106.9 - $167.73 $730,127 - $1.15 Million
-6,830 Closed
0 $0
Q4 2020

Feb 16, 2021

BUY
$84.4 - $177.39 $576,452 - $1.21 Million
6,830 New
6,830 $945,000

Others Institutions Holding RARE

About Ultragenyx Pharmaceutical Inc.


  • Ticker RARE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 70,036,896
  • Market Cap $3.81B
  • Description
  • Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast...
More about RARE
Track This Portfolio

Track Twinbeech Capital LP Portfolio

Follow Twinbeech Capital LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Twinbeech Capital LP, based on Form 13F filings with the SEC.

News

Stay updated on Twinbeech Capital LP with notifications on news.